drugset / Trial / NCT03151486
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants
RandomizedParallel-groupDouble-blindOther
Summary
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-55308942 in healthy participants after administration of single and multiple oral doses.
Timeline
- Start
- 2017-05-03
- Primary completion
- 2018-03-08
- Completion
- 2018-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZANVIPIXANT | Small molecule | 0.5 mg | Oral |
| Subject | ZANVIPIXANT | Small molecule | 1.5 mg | Oral |
| Subject | ZANVIPIXANT | Small molecule | 4 mg | Oral |
| Subject | ZANVIPIXANT | Small molecule | 12 mg | Oral |
| Subject | ZANVIPIXANT | Small molecule | 36 mg | Oral |
| Subject | ZANVIPIXANT | Small molecule | 100 mg | Oral |
Indications
No indication recorded.